Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: Associations with carotid intima-media thickness

Diabetic Medicine

Volumn 23, Issue 9, 2006, Pages 955-966

  Lyons, T J ^a,b,f   Jenkins, A J ^a,b,c   Zheng, D ^b   Klein, R L ^b   Otvos, J D ^d   Yu, Y ^a   Lackland, D T ^b   McGee, D ^b   McHenry, M B ^b   Lopes Virella, M ^b   Garvey, W T ^b,e  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d NORTH CAROLINA STATE UNIVERSITY   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Atherosclerosis; Diabetes mellitus; Lipoproteins; Nuclear magnetic resonance; Subclinical disease

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHYLOMICRON; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN;

ADOLESCENT; ADULT; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; FEMALE; GENDER; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RISK FACTOR; THICKNESS;

ADULT; BODY CONSTITUTION; CAROTID ARTERY, COMMON; CAROTID ARTERY, INTERNAL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; LIPOPROTEINS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; TUNICA INTIMA; TUNICA MEDIA;

EID: 33747498768     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01905.x     Document Type: Article

References (50)

1. Touboul PJ, Crouse JR III. Intima-Media Thickness and Atherosclerosis: Predicting the Risk? New York: Parthenon Publishing Group, 1997.
2. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14-22.
3. Kawamori R, Yamasaki Y, Matsushima H, Nishizawa H, Nao K, Hougaku H et al. Prevalence of carotid atherosclerosis in diabetic patients. Ultrasound high-resolution B-mode imaging on carotid arteries. Diabetes Care 1992; 15: 1290-1294.
4. Yamasaki Y, Kawamori R, Matsushima H, Nishizawa H, Kodama M, Kajimoto Y et al. Atherosclerosis in carotid artery of young IDDM patients monitored by ultrasound high-resolution B-mode imaging. Diabetes 1994; 43: 634-639.
5. Pujia A, Gnasso A, Irace C, Colonna A, Mattioli PL. Common carotid arterial wall thickness in NIDDM subjects. Diabetes Care 1994; 17: 1330-1336.
6. Bonora E, Tessari R, Micciolo R, Zenere M, Targher G, Padovani R et al. Intimal-medial thickness of the carotid artery in non-diabetic and NIDDM patients. Relationship with insulin resistance. Diabetes Care 1997; 20: 627-631.
7. Krantz JS, Mack WJ, Hodis HN, Liu CR, Liu CH, Kaufman FR. Early onset of subclinical atherosclerosis in young persons with type 1 diabetes. Diabetes 1994; 43: 634-639.
8. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res 1987; 28: 613-628.
9. Pyorala K. Diabetes and heart disease. In: Mogensen CE, Standl E, eds. Prevention and Treatment of the Diabetic Late Complications. New York: Walter de Gruyter, 1989: 151-168.
10. Lyons TJ. Glycation and oxidation: a role in the pathogenesis of atherosclerosis. Am J Cardiol 1993; 71: 26B-31B.
11. Jenkins AJ, Best JD, Klein RL, Lyons TJ. Lipoproteins, glycoxidation and diabetic angiopathy. Diabetes Metab Res Rev 2004; 20: 349-368.
12. Superko HR. New aspects of risk factors for the development of atherosclerosis, including small dense lipoprotein, homocyst(e)ine, and lipoprotein (a). Curr Opin Cardiol 1995; 10: 347-354.
13. Austin MA. Small, dense low-density lipoprotein as a risk factor for coronary heart disease. Int J Clin Lab Res 1994; 24: 187-192.
14. Colhoun HM, Otvos JD, Rubens MB, Taskinen MR, Underwood SR, Fuller JH. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without Type 1 diabetes. Diabetes 2002; 51: 1949-1956.
15. Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ, Pittsburgh Epidemiology of Diabetes Complications Study. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia 2003; 46: 674-682.
16. The Diabetes Care and Complications Trial (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
17. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999; 22: 99-111.
18. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 1999; 48: 383-390.
19. The Diabetes Care and Complications Trial (DCCT) Research Group. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 1987; 33: 2267-2271.
20. Otvos JD, Jeyarajah EJ, Bennett DW. Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy. Clin Chem 1991; 37: 377-386.
21. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D et al. Serum lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications cohort: associations with gender and glycemia. Diabetes Care 2003; 26: 810-818.
22. Jenkins AJ, Klein RL, Chassereau C, Hermayer KL, Lopes-Virella M. Susceptibility to in vitro oxidation of LDL from patients with well-controlled IDDM is not increased. Diabetes 1996; 45: 762-767.
23. Glagov S, Zarins C, Giddens DP, Ku DN. Hemodynamics and atherosclerosis. Insights and perspectives gained from studies of human arteries. Arch Pathol Lab Med 1988; 112: 1018-1031.
24. Kiechl S, Willeit J. The natural course of atherosclerosis. Part I: incidence and progression. Arterioscler Thromb Vasc Biol 1999; 19: 1484-1490.
25. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-2303.
26. Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA. Lipoprotein subclasses and coronary artery calcium in post-menopausal women from the Healthy Women Study. Am J Cardio 2002; 90: 71i-76i.
27. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 1998; 18: 1046-1053.
28. Grundy SM, Vega GL. Two different views of the relationship of hypertriglyceridemia to coronary heart disease. Implications for treatment. Arch Intern Med 1992; 152: 28-34.
29. Tatami R, Mabuchi H, Ueda K, Ueda R, Haba T, Kametani T et al. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation 1981; 64: 1174-1184.
30. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation 1987; 75: 124-130.
31. Mack WJ, Krauss R, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS): treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996; 16: 697-704.
32. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH et al. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997; 95: 2022-2026.
33. Maeno Y, Kashiwagi A, Nishio Y, Takahara N, Kikkawa R. IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells. Diabetes Res Clin Pract 2000; 48: 127-138.
34. Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D et al. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy. Kidney Int 2003; 64: 817-828.
35. Jadhav UM, Kadam NN. Apolipoproteins: correlation with carotid intimamedia thickness and coronary artery disease. J Assoc Physicians India 2004; 52: 370-375.
36. Wallenfeldt K, Bokemark L, Wikstrand J, Hulthe J, Fagerberg B. Apolipoprotein B/apolipoprotein A-I in relation to the metabolic syndrome and change in carotid artery intima-media thickness during 3 years in middle-aged men. Stroke 2004; 35: 2248-2252.
37. Alaupovic P. The concept of apolipoprotein-defined lipoprotein families and its clinical significance. Curr Atheroscler Rep 2003; 5: 459-467.
38. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, Garvey WT et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-918.
39. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterioscler Thromb Vasc Bio 2002; 22: 1175-80.
40. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 2002; 106: 1930-1937.
41. Yokoyama H, Aoki T, Imahori M, Kuramitsu M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int 2004; 66: 448-454.
42. Klein R, Sharrett AR, Klein BE, Moss SE, Folsom AR, Wong TY et al. The association of atherosclerosis, vascular risk factors, and retinopathy in adults with diabetes: the Atherosclerosis Risk in Communities Study. Ophthalmology 2002; 109: 1225-1234.
43. Rema M, Mohan V, Deepa R, Ravikumar R, Chennai Urban Rural Epidemiology Study 2. Association of carotid intima-media thickness and arterial stiffness with diabetic retinopathy: the Chennai Urban Rural Epidemiology Study (CURES-2). Diabetes Care 2004; 27: 1962-1967.
44. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003; 52: 453-462.
45. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
46. Olson JC, Erbey JR, Williams KV, Becker DJ, Edmundowicz D, Kelsey SF et al. Subclinical atherosclerosis and estimated glucose disposal rate as predictors of mortality in type 1 diabetes. Ann Epidemiol 2002; 12: 331-337.
47. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2003; 26: 1374-1379.
48. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, Hitman GA et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 2003; 167: 243-255.
49. Guerin M, Bruckert E, Dolphin PJ, Turpin G, Chapman MJ. Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile combined hyperlipidemia. Arterioscler Thromb Vasc Biol 1996; 16: 763-772.
50. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study. J Atheroscler Thromb 2004; 11: 278-285.